Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
News|Videos|March 14, 2024
Crisis Point: Stigma Hinders Adoption of Hepatitis C-Positive Donor Kidneys
Author(s)Abigail Brooks, MA, Patrick Campbell
To acknowledge World Kidney Day, our latest episode of Crisis Point focuses on the stigma surrounding the use of HCV-positive donor kidneys amid the ongoing organ shortage crisis, with the perspective of a pair of experts and an HCV donor kidney recipient.
Advertisement
Advertisement
This is Crisis Point.
Related to this article
ORKA-001, a half-life extended IL-23p19 antibody, achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B psoriasis trial.
In PHINDER, IPF had the highest PVD-B65 mortality risk scores. Rali discusses why PH in ILD is missed and when to refer for right heart catheterization.
Parth Rali, MD, explains how the AHA/ACC A-through-E categories compare with ESC risk tiers and how hospitals can meet the class 1 PERT recommendation.
Colin Church, MBBS, PhD, discusses durable 6MWD and NT-proBNP signals in a TPIP open-label extension and what phase 3 needs to show next.
Colin Church, MBBS, PhD, discusses 24-month open-label extension data showing TPIP remains tolerable in patients with PH-ILD, with no new safety signals.
Vanda’s oral NK-1 receptor antagonist cut any vomiting by 27% vs placebo after a single 1 mg semaglutide dose, and the company plans an sNDA submission.
This segment of Nguyen's 2026 Fall Clinical Dermatology interview highlights key insights on early dermatology career strategies and other information.
Advertisement
Advertisement